Soybeans were treated with proteases to reduce allergeni city. By immunoblotting with a monoclonal antibody against a major soybean allergen (Gly m Bd 30K), two of eight proteases so far tested were selected to achieve a reduction in allergenicity. Both antigenicity to the monoclonal antibody and allergenicity to the sera from soybean sensitive patients proved to be markedly reduced by processing with either protease. Thus, soybeans treated with an appropriate protease may possibly be supplied as a hypoallergenic foodstuff for patients.
soybean food "natto" was demonstrated to be a hypoallergenic soy product; its allergenicity having been considerably reduced by the action of secretory proteases from Bacillus subtilis (10) .
In this report, we treated soybean proteins with various proteases and moni tored alterations in their antigenicity to the monoclonal antibody or allergenicity to patients' sera for the purpose of developing hypoallergenic soybean foods. MATERIALS AND METHODS antigenicity for IgE contained in patients' sera (Fig. 4) . In either case, the autoradiographic patterns revealed that the higher the concentration of each protease, the weaker the IgE binding bands became.
Materials

DISCUSSION
From the eight proteases we tested, we selected Proleather and Protease N, both of which are produced by Bacillus subtilis, as the most suitable proteases for alleviating the allergenicity of soybean. As these two proteases were not specific for Gly m Bd 30K, hydrolyzing all the proteins in soybean was required for the destruction of this major allergen. In processing soybeans, we monitored only the antigenicity of the major allergen (Gly m Bd 30K) using its specific monoclonal antibody. Consequently, the protease-treated soybean, where the antigenicity of Gly m Bd 30K was not detectable in practice, was lacking in the allergenicity to the patients' sera, which could detect some other proteins as well as Gly m Bd 30K. Thus, the protease-treated soybean we prepared this time may be appropriate as a hypoallergenic and safe food for the many patients who are sensitive to soybean. In addition, the protease-treated soybean has no peculiar flavor or taste as opposed to most fermented products. Thus, we intend to utilize the protease-treated soybean as a foodstuff for "boiled beans."
Several hypoallergenic foods are commercially available today. For example, in Japan, we can purchase hypoallergenic infant formula and hypoallergenic rice at the market. Such foods are beneficial to patients who are allergic to these foods. Soybean is not always a common allergenic food in the western world. In Japan, however, soybean is considered to be a member of three major allergenic foods with a high frequency of occurrence. Thus, the development of hypoallergenic soybean foods is meaningful in this country. In the western world, it has been reported that an allergy to soybean occurs when soya milk has been used as a substitute for cow's milk (14) . If people in these areas began to ingest soyproteins more often, the number of allergic patients sensitized by soybean would increase.
The two proteases we selected were effective in hydrolyzing autoclaved soy beans, although not so effective for merely soaked soybeans. When these enzymes were added to extract protein from soybean, it was possible to hydrolyze Gly m Bd 30K as well as other proteins in soybean (data not shown). This suggests that some structural barrier of the intact soybean inhibited the penetration of protease into the soybean cotyledons. If it were possible to remove such barrier, the intact soybean could be treated as a modifying target to reduce allergenicity .
Of course, to thoroughly evaluate the reduction of allergenicity, skin and oral challenge tests are necessary. The oral challenge test of the protease-treated soybean is now in progress. 
